MAXILUS
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 100 patients (estimated)
- Sponsors
- Bristol Myers Squibb
- Tags
- Erythroid Maturation Agent (EMA), Red Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1768
- NCT Identifier
- NCT06045689
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.